



## References:

- \* Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
- ^ Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228. doi:10.1182/blood.2022015850

## World Health Organization Criteria for Systemic Mastocytosis (SM)\*

Diagnosis of SM can be established if at least 1 major AND 1 minor OR 3 minor criteria are met

## International Consensus Classification of Systemic Mastocytosis (SM)^

Diagnosis of SM can be established if at least 1 major OR 3 minor criteria are met

### – Major criteria

Multifocal dense infiltrates of mast cells (MC) in bone marrow (BM) biopsies or in section of other extracutaneous organs

### – Minor criteria

- More than 25% of all MCs are atypical (type I or II) or spindle-shaped
- KIT Asp816Val point mutation present
- MCs exhibit CD2 or CD25
- Baseline serum tryptase is >20 ng/mL, unless there is an associated myeloid neoplasm, in which case this parameter is not valid.